We are live on !
Find out more
BVF Inc Portfolio holdings
AUM
$3.04B
Turnover
10.42%
1-Year Est. Return
129.63%
This Fund
S&P 500
This Quarter Est. Return
+4.92%
1 Year Est. Return
+129.63%
3 Year Est. Return
+531.24%
5 Year Est. Return
+1,335.11%
10 Year Est. Return
+16,856.28%
AUM
$515M
AUM Growth
–
Cap. Flow
+$483M
Cap. Flow % of AUM
Cap. Flow %
93.73%
Top 10 Holdings %
Top 10 Hldgs %
87.64%
Holding
24
New
22
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
years
Top 10 Avg Time Held
0
years
Top 20 Avg Time Held
0
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ligand Pharmaceuticals
LGND
|
+$104M |
| 2 |
Ironwood Pharmaceuticals
IRWD
|
+$76M |
| 3 |
ChemoCentryx
CCXI
|
+$65.1M |
| 4 |
Array Biopharma
ARRY
|
+$59.9M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$44.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88% |
| 2 | Miscellaneous | 12% |
Similar funds
BVF Inc's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for BVF Inc, which disclosed 24 positions worth $515M. Its ten largest holdings account for 88% of the portfolio.
Its largest position is Ligand Pharmaceuticals: 5,805,529 shares worth $136M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, followed by Miscellaneous.
- BVF Inc's largest Q2 2013 buy was Ligand Pharmaceuticals: 5,805,529 shares worth $136M.
- BVF Inc's ten largest holdings make up 88% of its $515M portfolio in Q2 2013.
- BVF Inc disclosed 24 positions in Q2 2013, its first 13F filing on record.
Based on BVF Inc's 13F filing for Q2 2013, filed 14 Aug 2013.